This May 2025, the FDA approved a blood test that’s 97% accurate for Alzheimer’s – beating invasive spinal taps. For APOE4 carriers, this changes everything about early diagnosis, disease progression tracking, and more!
In this comprehensive analysis of 9 breakthrough biomarker presentations, I reveal game-changing advances that are available RIGHT NOW for APOE4 carriers.
No more waiting for future breakthroughs – these tools exist today.
[KEY FINDINGS]
• P-tau217 blood test: 97% accurate, available NOW at Quest/LabCorp ($300-400)
• QGRE MRI: Detects 5-10% neuron loss (vs 20-30% for regular MRI) in 6 minutes
• Mobile Toolbox: Smartphone app detects “loss of practice effect” 5-7 years before symptoms
• AI prediction: 85% accurate within 2-3 year windows for disease progression
• Women: Lose 2% more gray matter per inflammation unit than men
• MTBR markers: Predict cognitive decline with 0.74 correlation coefficient
Want to take action?
Join the Phoenix Community to beat the odds and outsmart Alzheimer’s
→
Get the free ebook: Essential Guide to Thriving with APOE4
→
Subscribe to my newsletter: Join thousands of APOE4 getting weekly research breakdowns
→
[TIMESTAMPS]
00:00 FDA Approves First Alzheimer’s Blood Test
02:45 P-tau217: Why 97% Accuracy Changes Everything
05:30 Blood Test BEATS Spinal Tap (The Data)
08:15 6-Minute MRI Sees Damage Before Shrinkage
11:00 NIH Smartphone App Detects Changes 7 Years Early
14:30 AI Predicts Your Personal Timeline
17:00 MTBR: Tracking Tau’s Most Dangerous Form
19:45 Women Face Double Jeopardy with Inflammation
22:30 Multiple Conditions Multiply Risk
25:00 11-Protein Panel Creates Disease Fingerprint
27:30 Action Steps You Can Take TODAY
Session Presenter(s):
Daeun Shin (Samsung Medical Center, Seoul, Korea, Republic of (South)) – Biomarker-integrated Prognostic Stagings for Alzheimer’s Disease
Satya V.V.N. Kothapalli (Washington University School of Medicine in St. Louis, MO, USA) – Pre-atrophic Neurodegeneration: A Novel MRI-Based Biomarker for Early Neuronal Injury Coincident with Early Amyloid Accumulation
Noëlle Warmenhoven (Lund University, Sweden) – Comparison of plasma biomarkers measured on a fully automated instrument versus CSF biomarkers for detecting Alzheimer’s disease pathology
Xiaqing Jiang (University of California, San Francisco, CA, USA) – AT(N) Biomarkers Across Modalities in the Pathways Between Multimorbidity and Cognition
Katie L. Vandeloo (Hurvitz Brain Sciences Program, Sunnybrook Research Institute, ON, Canada) – Sex-Specific Associations Between Systemic Inflammation and Brain Health in Aging: Evidence from a Multi-Ethnic Canadian Cohort
MarĂa Fernanda Zambrano-Astorga (CICESE, BJ, Mexico) – Identification of an Alzheimer’s Disease Biomarker Signature Using Reproducible Proteomics Data Mining
Christopher S. Parker (UCL Hawkes Institute and Department of Computer Science, University College London, United Kingdom; Dementia Research Centre, Queen Square Institute of Neurology, Greater London, United Kingdom) – Longitudinal trajectories of advanced cortical diffusion-weighted imaging measures of tissue microstructure in pre-symptomatic autosomal dominant Alzheimer’s disease
Roos J. Jutten (Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Netherlands) – The remote Mobile Toolbox for capturing cognitive change in preclinical Alzheimer’s disease
Fernando Gonzalez-Ortiz (University of Gothenburg, Department of Psychiatry And Neurochemistry, Institute of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg, Sweden) – Novel MTBR-specific immunoassays MTBR-1 and MTBR-pTau262 for assessment of tau pathology in Alzheimer’s disease
source